𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B

✍ Scribed by Jason R. Clark; Kathryn Bartley; Catherine D. Jepson; Vicki Craik; John B. March

Book ID
109309725
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
212 KB
Volume
61
Category
Article
ISSN
0928-8244

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Comparison of a triple antigen and a sin
Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination
✍ Michael D. Young; W. Manford Gooch III; Arie J. Zuckerman; Wei Du; Brian Dickson πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 130 KB

## Abstract Hepatitis B and its sequelae are a major public health problem. Vaccines have been available for almost 20 years; however the disease still remains a global problem. Many factors contribute to the failure to control hepatitis B, including the limited nature of the vaccination programs i

Characterization of a human monoclonal a
Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine
✍ R.A. Heijtink; J. Kruining; P. van Bergen; S. de Rave; J. van Hattum; M. Schutte πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 204 KB

A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB-VAX: plasmaderived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix-B). 1Ff4 binds preferentially to HBs

Immunogenicity of 20 ΞΌg of recombinant D
Immunogenicity of 20 ΞΌg of recombinant DNA hepatitis B vaccine in healthy neonates: A comparison of three different vaccination schemes
✍ R. Del Canho; P. M. Grosheide; M. Voogd; W. M. Huisman; R. A. Heijtink; Dr. S. W πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 558 KB

## Abstract The immunogenicity of a full dose (20 ΞΌg) of recombinant DNA yeast‐derived hepatitis B vaccine (Engerix‐B) was assessed in healthy neonates in order to compare three candidate vaccination schemes. After randomization 162 newborns of hepatitis B surface antigen (HBsAg) negative mothers e